Nkarta (NKTX) Non Operating Investment Income (2022 - 2026)
Nkarta's (NKTX) quarterly Non Operating Investment Income came in at -$537000.0 in Q1 2026, down 2340.91% year-on-year from $23963.5 in Q1 2025, and down 316.28% quarter-over-quarter from -$129000.0 in Q4 2025.
Nkarta (NKTX) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Nkarta's Non Operating Investment Income history runs 5 years deep, the most recent figure standing at -$537000.0 for Q1 2026.
- On a quarterly basis, Non Operating Investment Income fell 2340.91% year-over-year to -$537000.0 in Q1 2026; TTM through Mar 2026 was -$782000.0, a 200.39% decrease from a year earlier, with the FY2025 full-year figure at -$267000.0, down 140.09% from the prior year.
- Non Operating Investment Income fell to -$537000.0 in Q1 2026 per NKTX's latest filing, from -$129000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $2.0 million in Q3 2024 and bottomed at -$1.0 million in Q4 2024.
- The 5-year median for Non Operating Investment Income is -$135000.0 (2024), against an average of $1176.5.
- Across the five-year window, Non Operating Investment Income soared 929.69% in 2024 and sank 2340.91% in 2026, its largest moves.
- Year by year, Non Operating Investment Income stood at $642000.0 in 2022, then slumped by 35.05% to $417000.0 in 2023, then plunged by 349.4% to -$1.0 million in 2024, then jumped by 87.6% to -$129000.0 in 2025, then tumbled by 316.28% to -$537000.0 in 2026.
- Per Business Quant, the three latest NKTX Non Operating Investment Income figures stand at -$537000.0 (Q1 2026), -$129000.0 (Q4 2025), and $174000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Nkarta | 168.94 Mn | 168.94 Mn | - | -537,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -537,000.00 |
| Mar 31, 2026 | -537,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Sep 30, 2025 | 174,000.00 |
| Sep 30, 2025 | 174,000.00 |
| Jun 30, 2025 | -290,000.00 |
| Jun 30, 2025 | -290,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | -1.04 Mn |
| Dec 31, 2024 | -1.04 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | -136,000.00 |
| Jun 30, 2024 | -136,000.00 |
| Mar 31, 2024 | -135,000.00 |
| Mar 31, 2024 | -135,000.00 |
| Dec 31, 2023 | 417,000.00 |
| Dec 31, 2023 | 417,000.00 |